You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

498 Results
The following information answers many of the questions primary care physicians commonly ask about the Screening Activity Report and the included...
A variety of screening tools and resources are available to support the screening activities of primary care providers, nurses and specialists.
Document
New
Jul 2025
Drug
Other Name(s): Tecentriq® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Drug
Other Name(s): Tecentriq™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Symptom Management
Statistical Reports
Aug 2020
Statistical Reports
Apr 2023
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Sacituzumab Govitecan - Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
New Drug Funding Program
    Sacituzumab Govitecan - HR-positive HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
sacituzumab govitecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    abiraterone
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abiraterone,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025

Pages